8/11 Targeting Anti-inflammatory Gene Expression in Binge-like Drinking
- Institution
- Oregon Health & Science University, OR
- Principal investigator
- Angela Renee Ozburn
- Funding
- $377K
- Duration
- 2001–2027
Moonbase score
Still being scored
Abstract
Project Summary High Drinking in the Dark (HDID) mice have been selectively bred to drink to intoxication. HDID mice are genetically distinct and represent a unique genotype for drug screening. Many of the compounds that reduce drinking in other strains (e.g., C57BL/6J) do not reduce drinking in HDID mice, and also fail to reduce drinking in humans. Many INIA-Neuroimmune studies have found that alcohol alters inflammatory signaling. We employed a rigorous approach for testing whether several compounds targeting immune signaling could reduce binge-like drinking in HDID mice. To date, 14 out of 28 compounds tested in HDID mice were able to reduce binge-like drinking in HDID mice. Apremilast, a phosphodiesterase type 4 inhibitor and our most promising clinical target, and other compounds that reduced binge-like drinking have one thing in common - they increase anti-inflammatory (e.g. IL-10) signaling. These results offer a broadly unifying hypothesis for more mechanistic experiments to investigate how the balance of pro- and anti-inflammatory signaling regulates binge-like drinking in HDID mice. Here, we study this mechanism in the context of initiation of binge-like drinking, and determine whether this framework holds true under chronic binge drinking conditions. An overarching goal of this proposal is to identify and target anti-inflammatory signatures to reduce drinking and restore alcohol-induced changes in anti- and pro-inflammatory signaling in the brain. Specfic Aim 1 tests whether specific inflammatory signaling pathways contribute to binge-like drinking in iHDID mice using a combination of complementary molecular, genetic, pharmacological, and behavioral approaches in collaboration with INIA-N PIs Roberto, Mangieri, Bilbo, and Lasek. Specific Aim 2 tests whether chronic binge- like drinking is accompanied and/or regulated by anti-inflammatory gene expression in iHDID-1 mice. Aim 2 will employ informatics approaches to identify compounds for behavioral and molecular studies in collaboration with INIA-N PI Mayfield. This project also collaborates with INIA-Stress PIs Vazey/Mooreman and Becker/Lopez to test the effects of promising compounds on other behaviors, and shares the HDID and HS/Npt mouse lines as unique resources developed and maintained under this award with investigators nationwide.
LOADING MOONBASE SCORE
Questions for Oregon Health & Science University
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · Oregon Health & Science UniversityNot yet scored
IRACDA at OHSU
Angela Renee Ozburn · $1.0M · 2023–2028
- NIH · Oregon Health & Science University60
mPFC Regulation of VTA Dopamine and GABA Neuronal Activity During Flexible Updating of Appetitive and Aversive Associations
Merridee Justice Lefner · $76K · 2024–2026
- NIH · Oregon Health & Science University59
Functional Mapping of the Suprachiasmatic Nucleus
Karen Jill Tonsfeldt · $224K · 2022–2028